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Abstract: Obstructive sleep apnea (OSA) affects one in five adult males and is associated with 
significant comorbidity, cognitive impairment, excessive daytime sleepiness, and reduced quality 
of life. For over 25 years, the primary treatment has been continuous positive airway pressure, 
which introduces a column of air that serves as a pneumatic splint for the upper airway, prevent-
ing the airway collapse that is the physiologic definition of this syndrome. However, issues with 
patient tolerance and unacceptable levels of treatment adherence motivated the exploration of 
other potential treatments. With greater understanding of the physiologic mechanisms associ-
ated with OSA, novel interventions have emerged in the last 5 years. The purpose of this article 
is to describe new treatments for OSA and associated complex sleep apnea. New approaches 
to complex sleep apnea have included adaptive servoventilation. There is increased literature 
on the contribution of behavioral interventions to improve adherence with continuous positive 
airway pressure that have proven quite effective. New non-surgical treatments include oral 
pressure devices, improved mandibular advancement devices, nasal expiratory positive airway 
pressure, and newer approaches to positional therapy. Recent innovations in surgical interven-
tions have included laser-assisted uvulopalatoplasty, radiofrequency ablation, palatal implants, 
and electrical stimulation of the upper airway muscles. No drugs have been approved to treat 
OSA, but potential drug therapies have centered on increasing ventilatory drive, altering the 
arousal threshold, modifying loop gain (a dimensionless value quantifying the stability of the 
ventilatory control system), or preventing airway collapse by affecting the surface tension. An 
emerging approach is the application of cannabinoids to increase upper airway tone.
Keywords: obstructive sleep apnea, innovative treatment, continuous positive airway pressure, 
oral appliance, nerve stimulation
Introduction
Obstructive sleep apnea (OSA) is a common problem. The second most diagnosed 
respiratory condition after asthma, 9%–28% of women and 24%–26% of males in the 
US population have apneic events at a treatable level, making this syndrome a serious 
public health issue.1 Untreated OSA has a profound effect on health and behavior, 
resulting in excessive daytime sleepiness, impaired cognition and mentation, decreased 
daytime function, and alterations in mood.1 OSA contributes to increased heart   disease, 
stroke, hypertension, diabetes, and obesity, with a high rate of comorbidity. The eco-
nomic burden of untreated OSA is enormous, having a cost similar in magnitude 
to diabetes, ie, 132 billion dollars in 2002, with an estimated $15.9 billion for the 
800,000 crashes attributed to OSA.2,3 From the perspective of the health care system, 
for each quality-adjusted life year, $3,354 and $11.1 billion in collision costs would Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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be saved with successful continuous positive airway pressure 
(CPAP) treatment, the primary intervention for OSA for over 
25 years.3 CPAP introduces a column of air that serves as a 
pneumatic splint for the upper airway, preventing the airway 
collapse that is the physiologic definition of this syndrome. 
Despite demonstrated efficacy and potential cost savings, 
the overall effectiveness of CPAP is significantly limited by 
poor adherence.4 This limitation has prompted the develop-
ment of new approaches to produce more tolerable designs 
for CPAP treatment, approaches to enhance adherence, and 
innovations in other interventions to treat OSA. With greater 
understanding of the physiologic mechanisms associated with 
OSA, novel interventions have emerged in the last 5 years. 
The purpose of this article is to describe new treatments for 
OSA and associated complex sleep apnea.
Advances in positive airway 
pressure treatment
Complex sleep apnea refers to a pattern of sleep-disordered 
breathing that includes both obstructive apneas/hypopneas 
and central apneas. Specifically, this occurs in patients 
without daytime hypercapnia. Central apneas are noted 
during non-rapid eye movement sleep and may “emerge” 
during CPAP titration. It is likely that these individuals 
have a high loop gain (a dimensionless value quantifying 
the stability of the ventilatory control system) in addition to 
a collapsible airway. Loop gain is measured by repeatedly 
dropping CPAP pressure during sleep to induce prolonged 
hypopneas, and then returning CPAP pressure to normal. 
The return of normal pressure causes an overshoot of 
ventilation, called the “response”. Loop gain is calculated 
by dividing “the response” by “the stimulus” (the differ-
ence between ventilation during the hypopnea and zero 
ventilation). A high loop gain approaching a value of 1 
reflects relative instability in the ventilatory system and 
predisposes to recurrent apneas. Adaptive servoventilators 
are spontaneous-timed bilevel positive airway pressure 
devices that estimate the patient’s minute ventilation and 
tidal volume and/or flow, and respond to it by delivering 
variable pressure support. Theoretically, this minimizes 
the hyperpneic phase (which precipitates central apneas). 
These devices provide better control of complex sleep 
apnea than other CPAP devices, particularly in patients 
with heart failure.6–8
The S9™ (ResMed Ltd, Bella Vista, Australia) is a novel 
CPAP device that includes a humidification system with a 
heated tube, reduced noise levels, and an adaptive positive 
airway pressure algorithm. Use of the S9 device resulted in 
longer average CPAP use by approximately 30 minutes after 
28 days in 50 patients with established CPAP use.9 A new 
CPAP modality, SensAwake® (Fisher and Paykel Healthcare 
Ltd, Auckland, New Zealand), was developed to monitor 
breathing patterns and reduce pressure with awakenings. 
When tested in a group of 42 CPAP-naïve patients with 
OSA, the SensAwake modality had results similar to those 
of traditional CPAP.10
Interventions to promote CPAP 
adherence
Adherence is the major obstacle to effective CPAP treatment. 
A Cochrane Collaboration report reviewing 30   studies of 
educational, supportive, and behavioral interventions con-
cluded that all three types of interventions had a positive 
impact on CPAP usage in 2,047 adults with OSA.11 There 
was moderate-quality evidence to support a modest increase 
in adherence to CPAP using short-term educational interven-
tions and low-quality evidence to support a large increase 
in CPAP adherence using behavioral interventions such as 
cognitive behavioral therapy and motivational interviewing. 
Recently, Bartlett et al conducted a randomized controlled 
study comparing a group cognitive behavioral therapy 
intervention with a social interaction control on CPAP 
  adherence.12 They found no difference between groups in 
CPAP adherence or self-efficacy using CPAP at 1 or 6 months. 
In another randomized controlled study, Deng et al com-
pared a stage-matched intervention with usual care in newly 
diagnosed OSA patients.13 Participants in the intervention 
group received care based on their stage of behavior change. 
Interventions ranged from education about OSA (stage 1) to 
setting and attaining goals for increased CPAP use at night 
(stage 4). They found significant differences between groups 
with regard to CPAP adherence at 1 and 3 months, and in the 
percentage of subjects using CPAP for more than 4 hours per 
night.13 Sawyer et al tested a risk screening questionnaire, ie, 
the Index for Nonadherence to PAP, for CPAP nonadherence 
in a longitudinal study that included 97 subjects with newly 
diagnosed OSA. The final Index for Nonadherence to PAP 
model included 19 items with questions regarding health 
literacy, self-efficacy, body mass index (BMI), marriage sta-
tus, presenting symptoms, and gender. The questionnaire 
successfully identified CPAP nonadherers and may provide 
a tool for early intervention development to decrease or pre-
vent nonadherence.14 Although there is growing evidence to 
support educational and behavioral interventions to enhance 
adherence with CPAP, further studies with stronger designs 
and larger samples are needed.Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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Nasal expiratory positive airway 
pressure
During the five distinct phases of the respiratory cycle, the 
final expiratory phase has the greatest risk of airway   occlusion. 
At the end of expiration, there is neither positive pressure 
nor inspiratory phasic activation of the upper airway dilator 
muscles.15 Moreover, there is significant narrowing of the 
upper airway during expiration preceding apnea,16 and the 
lowest cross-sectional of the upper airway occurs during 
expiration.17–19 The nasal expiratory positive airway pressure 
(nEPAP) device allows for low inspiratory resistance while 
increasing expiratory resistance to prevent upper airway 
collapse (see Figure 1).18,19 It comprises a single-use device 
containing a mechanical valve that can create high expiratory 
resistance, with very low inspiratory resistance applied to each 
nostril with an adhesive to provide a seal.20,21 There have been 
six clinical trials using nEPAP.18,20–24 In all studies, there was 
a significant decrease in apnea-hypopnea index (AHI). Four 
of the nEPAP studies were uncontrolled,   proof-of-concept 
studies,18,20,23,24 one was a prospective, sham-controlled, ran-
domized, double-blind, multicenter clinical trial,21 and another 
was an extension of the latter clinical trial to observe long-term 
treatment durability and safety.22
In the proof-of-concept studies, two used nEPAP 
devices of varying expiratory resistances to increase 
tolerability.20,24 In these proof-of-concept studies, there 
was a 31%–49% decrease in AHI.18,20,23,24 Two studies 
showed no difference in sleep architecture,18,20 and one 
study showed significant changes in sleep architec-
ture.24 Two studies quantified and showed significant 
improvements in daytime sleepiness or sleep quality,20,24 
and three studies quantified and showed significant 
improvement in oxygen saturation.8,20,24 The results of 
the proof-of-concept trials are encouraging. However, as 
with CPAP,25 tolerability and adherence to nEPAP was an 
issue. Although self-reported use was as high as 94%,20,24 
15% of participants in one study failed to take the device 
home.20 In another study, there was a dropout rate of 22% 
due to lack of tolerability of nEPAP, and many adverse 
events like difficulty breathing and sleeping, dry mouth, 
and nasal discomfort were reported.24
A prospective, sham-controlled, double-blind, multicenter 
clinical trial randomized newly diagnosed or previously diag-
nosed but untreated OSA patients to either nEPAP or a sham 
group.21 The sham treatment device was similar to the nEPAP 
device, with the only difference being that the sham device 
contained valves that did not provide expiratory resistance. 
The participants wore the nEPAP/sham devices for 3 months 
with two nonconsecutive night sleep studies a week into the 
study and two nonconsecutive night sleep studies at the end 
of the 3 month study period. The two nonconsecutive night 
sleep studies were done to evaluate on-device and off-device 
polysomnographs (randomly assigned). Significant median 
decreases in AHI after 1 week and 3 months of nEPAP were 
53% and 43%, respectively, when compared with sham. 
There were also significant decreases in oxygen desatura-
tion index, Epworth Sleepiness Scale, and arousal index, 
and significant changes in sleep architecture between the 
nEPAP and sham groups. Adherence was high in both the 
nEPAP and sham groups; however, there was significantly less 
adherence in the nEPAP group than in the sham group (88.2% 
versus 92.3%). Adverse events, like difficulty exhaling, nasal 
discomfort, dry mouth, headache, and insomnia, were not 
significantly different between the two groups; however, more 
participants dropped out of the nEPAP group due to adverse 
events. A follow-up study evaluated the long-term durability 
of treatment response and safety of nEPAP.22 The positive 
results obtained from the original 3-month study21 were repli-
cated after 12 months of wearing nEPAP.22 As in the 3-month 
study, adverse events were still reported.21,22
Although AHI is an important metric to quantify improve-
ments in treatment response, another outcome that is impor-
tant to the user as well as his or her sleeping partner is that 
of snoring. In three studies, the percentage of total sleep 
time spent snoring decreased significantly by 57.8%–74.4% 
with use of nEPAP, providing a quieter environment for the 
sleeping partner.18,20,22
Figure 1 Photograph of the expiratory positive airway pressure device in place. 
Notes: Reprinted from Sleep Med, 12(2), Walsh JK, Griffin KS, Forst EH, et al. 
A convenient expiratory positive airway pressure nasal device for the treatment 
of sleep apnea in patients non-adherent with continuous positive airway pressure, 
147–152, Copyright © 2011, with permission from elsevier.24Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
140
weaver et al
The significant improvements in AHI, oxygen   saturation, 
and snoring with nEPAP are very encouraging, and the 
improvement in snoring suggests that this treatment may be 
suitable for those with mild OSA. Moreover, given the chal-
lenges of traveling with a CPAP device, nEPAP may be an 
alternative for patients who travel frequently. As with CPAP, 
adherence and tolerability are an issue. However, considering 
the ease of application, compact design, low cost, and avail-
ability of these devices (ie, accessible without a prescription), 
nEPAP may become a second-line therapy to CPAP.
Oral pressure therapy
Oral pressure therapy, in which a vacuum is applied to the 
oropharynx to pull the soft palate forward and stabilize the 
tongue, has recently been studied in adult patients with OSA.26 
The system, such as the Winx device (see Figure 2), includes 
a mouthpiece in a number of sizes, a vacuum pump, a console, 
and tubing. While breathing normally through the nose, con-
tinuous negative pressure in the oral cavity moves the soft pal-
ate forward into contact with the tongue to reduce   obstruction. 
The negative pressure is isolated from the nasopharyngeal 
airway by the natural seal that occurs between the soft palate 
and tongue. In a   multicenter,   prospective, randomized, cross-
over trial,   Colrain et al evaluated the safety and efficacy of an 
oral pressure therapy system in subjects with mild to severe 
OSA.27 The therapy was well tolerated and used on average 
for 6 hours at night. Oral pressure therapy was associated 
with clinically significant improvements in AHI, sleep qual-
ity and continuity, and daytime sleepiness.27 Although there 
is preliminary evidence to support oral pressure therapy as a 
therapy for OSA, additional studies with strong designs and 
larger samples are needed.
Oral appliance innovations
Although not a new concept, novel oral appliances, such as 
tongue repositioning or restraining devices, have recently 
been tested in people with OSA. A tongue-stabilizing device 
that uses suction to protrude the tongue was compared with a 
mandibular advancement device in a randomized crossover 
study of a small sample of patients recruited from a tertiary 
hospital sleep clinic.28 Although the AHI was significantly 
improved with both the mandibular advancement device 
and the tongue-stabilizing device, compliance was poor for 
the tongue-stabilizing device, with participants preferring 
the mandibular advancement device. A full breath solution 
appliance was examined in adults diagnosed with OSA. This 
is an oral appliance that has a horizontal transpalatal bar with 
a vertical extension called the posterior tongue restrainer. 
The transpalatal bar and tissue make contact above the 
tongue and below the palatal mucosa when the person is 
supine during sleep, theoretically restraining and inhibit-
ing the tongue from obstructing the upper airway. In this 
preliminary study, the mean AHI fell by 73% and the mean 
SaO2 significantly improved.29 Dort and Remmers tested a 
combined approach using a mandibular repositioning appli-
ance with an attached tongue-retaining device; the desired 
Figure 2 (A) winx device, an oral pressure device that uses gentle suction to 
anteriorly and superiorly displace the tongue and the soft palate. (B) effect of oral 
pressure device on the tongue and soft palate displacement. 
Notes:  Copyright  ©  2013.  Reproduced  with  permission  from  the  American 
College  of  Chest  Physicians.  Park  JG,  Morgenthaler  TM,  Gay  PC.  Novel  and 
emerging nonpositive airway pressure therapies for sleep apnea. Chest. 2013;144(6): 
1946–1952.19Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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response (respiratory disturbance index ,10 events per hour) 
was achieved in 34% of subjects, but many subjects (39%) 
were nonresponders.30 The authors concluded that patients 
require several weeks to acclimate to the device and achieve 
an optimal response, which may explain the poor response 
rate in this study.
Ngiam and Kyung investigated a novel mandibular 
advancement device that involved mini-implants and a 
facemask as anchors.31 This device may be particularly 
beneficial in cases where there are too few teeth to retain 
the oral appliances, or in patients who cannot tolerate a 
bulky intraoral device. Albeit based on only ten subjects, the 
results showed a significant reduction in AHI and snoring 
frequency, although design alterations in the face pads were 
necessary to avoid pressure sores. Almeida et al showed 
how short-term oral appliances could be a viable treatment 
option in patients who are adherent to CPAP but need to 
pause use of the machine in certain circumstances, such as 
traveling or lack of power supply.32 Having both treatment 
options provided good outcomes and more convenience for 
the patients.
One factor enhancing the effectiveness of mandibular 
advancement device treatment is the ability to titrate the 
appliance to a patient’s specific needs. Titration protocols 
may be based on subjective parameters including patient 
comfort, objective parameters such as polysomnographic 
data, or both. To date, no consensus has been reached on a 
standardized titration protocol.33
In order to measure the overall therapeutic effectiveness 
of an oral appliance completely, objective compliance data 
must be obtained. To date, most relevant studies have relied 
on self-reporting. A thermosensor embedded in an oral 
appliance has been reported to have a high correlation with 
corresponding subjective reporting.34 This same method was 
studied long term, and after 1 year the correlation remained 
the same with respect to self-report.35 Although not currently 
in widespread clinical use, this provides a safe and effective 
method for obtaining objective reports on patient adherence. 
Further studies need to be conducted to determine the optimal 
battery life, power consumption, and storage capacity of such 
compliance trackers. Recently, Smith and Verrett investigated 
a novel device that included a supplementary sensor to enable 
conservation of power and memory.36 Their study also found 
a high correlation between subjective compliance reporting 
and data from their objective monitor. Objective compliance 
monitoring will be very valuable for long-term studies of 
oral appliance efficacy as well as interpreting outcomes of 
treatment.
Prediction of oral appliance 
treatment outcomes
Although oral appliance use for treating OSA has been stud-
ied extensively, it remains difficult to predict which patients 
will respond favorably to treatment with an oral appliance.37 
Moreover, there is a need for prospective long-term studies 
to evaluate success rates.37 Oropharyngeal crowding and 
obesity were studied as predictive factors for response to oral 
appliance therapy. Patients with moderate OSA who have 
oropharyngeal crowding, identified via Mallampati scoring, 
and who are obese were identified as poor responders to oral 
appliance therapy.38 Additional research has been conducted on 
craniofacial morphologic features as predictors for oral appli-
ance treatment. Cephalometric measurements such as increase 
in mandibular plane to cranial base angle are related to poor 
response to oral appliance treatment, whereas shorter soft palate 
length, increased cranial base angulation, minimal retroglossal 
airway, short anterior face height, and mandibular retrusion 
have been related to successful oral appliance treatment. These 
findings support the view that successful oral appliance treat-
ment is moderated by multiple anatomic factors.39,40 As dental 
professionals transition to three-dimensional imaging, further 
studies may be done utilizing three-dimensional landmarks 
and measurements to provide more accurate predictors of the 
outcome of oral appliance treatment. Recent studies utilizing 
magnetic resonance imaging, computed tomography, and cone-
beam computed tomography have all provided valuable airway 
volumetric data that are not provided by two-dimensional 
cephalograms alone.41–43 Future research using volumetric 
airway imaging may provide valuable insights into predicting 
individual responses to oral appliance therapy.
Another method that can evaluate lateral airway dimen-
sions aside from anteroposterior ones is nasal endoscopy. 
This method is promising as it is able to evaluate dynamic 
airway changes with an oral appliance either during sleep or 
wakefulness.44,45 In 2014, Sasao et al evaluated a number of 
patients diagnosed with sleep apnea and subjected them to 
a nasoendoscopic procedure while advancing the mandible. 
His group proposed conducting this test during wakefulness 
due to its clinical practicality compared with performing it 
overnight during sleep. They found that the orohypopharynx 
widened in all patients but the velopharynx only widened in 
approximately 75% of subjects, and that after oral appliance 
treatment, the AHI scores of those without velopharyngeal 
widening did not decrease significantly. The use of nasoen-
doscopy with mandibular advancement may be valuable in 
the future to evaluate velopharynx widening as a predictor 
of the efficacy of treatment with an oral appliance.45Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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Positional therapy
Sleep apnea in over half of patients with OSA is   position- 
dependent,46 defined as having at least double the AHI in the 
supine position compared with the lateral position.47   Studies 
of the effect of positional therapy on OSA have shown posi-
tive results, ie, lower efficacy than CPAP, but often with better 
adherence, despite being potentially uncomfortable.48 Recent 
studies examining the efficacy of position therapy based on 
position monitoring with a supine alarm49 and a sleep posi-
tion trainer device worn around the chest50 showed that these 
new devices were well tolerated and markedly reduced supine 
sleeping time and AHI. Additional studies of improved posi-
tional therapy devices are indicated.
Surgical treatment approaches
Upper airway, facial skeletal, and bariatric surgeries for mor-
bid obesity continue to offer important alternative treatment 
options for adult OSA. Surgical treatments may be selected 
based on patient preference and ability to tolerate or adhere to 
CPAP. Upper airway evaluation with a clinical staging system 
or dynamically with endoscopy during sleep/sedation, and 
with technologies such as cine magnetic resonance imaging, 
offer ways to localize upper airway anatomic compromise and 
tailor treatment to individual patients.51 Nasal surgery (eg, 
septoplasty, turbinectomy) can improve tolerability of CPAP 
therapy in selected patients with OSA and reduce snoring. 
Minimally invasive surgeries such as palatal implants and 
radiofrequency or laser-assisted uvulopalatopharyngoplasty 
are not efficacious in adult OSA and may be considered for 
primary snoring.52
Many adults do not respond to single operative interven-
tions and benefit from planned multilevel upper airway surgical 
modification either simultaneously or in staged protocols.53,54 
A common staged protocol involves utilizing uvulopalatophar-
yngoplasty with tongue suspension or with genioglossus 
advancement and hyoid myotomy (Phase I)55 and maxillary 
and mandibular advancement osteotomy (Phase II). Several 
new techniques of upper airway surgical modifications have 
recently been described. Submucosal lingualplasty in combina-
tion with palatal surgery was found to be effective in improv-
ing symptoms and AHI in a case series of OSA patients with 
  macroglossia.56 A transcervical technique to access the retro-
lingual space and perform radiofrequency ablation of hyper-
trophic lingual tonsils under sedation and local anesthesia has 
been reported and its effectiveness remains to be   established.57 
Other newly developed surgical approaches include modified 
uvulopalatopharyngoplasty and coblation   channeling of the 
tongue, a coblation-assisted Lewis and MacKay operation, and 
transpalatal advancement.58,59 An investigational technique, 
typically used within a staged surgical approach, is transoral 
robotic surgery for tongue base reduction.60
Mandibular advancement osteotomy results in a per-
manent increase in volume and reduction in length of the 
upper airway, and the extent of the anterior movements 
of the   maxilla, soft palate, and hyoid are correlated with 
improvement in AHI.61 The predictability of post-surgical 
airway change can be improved with virtual surgical plan-
ning, a technique that combines computed tomography imag-
ing with software reconstruction and surgical expertise.62 
Notwithstanding effects on AHI and symptoms, upper airway 
soft tissue and skeletal surgical interventions may improve 
quality of life, driving performance, and mortality rates in 
appropriately selected adults with OSA.63–66
Electrical stimulation
Remmers et al first suggested in 1978 that pharyngeal 
obstruction was related to loss of genioglossus muscle 
activity in OSA patients during sleep.67 Since then, several 
experimental methods to treat OSA have focused on electri-
cally stimulating upper airway muscle activity directly by 
transcutaneous, intraoral, or intramuscular electrodes (see 
Figure 3).68–72 Although these methods decreased the sever-
ity of OSA, they also had the unfortunate consequence of 
induced arousals and concomitant sleep fragmentation related 
to the electrical stimuli.
Figure 3 Schematic representation of the inspire™ i system for hypoglossal nerve 
stimulation in patients with obstructive sleep apnea. The stimulator (implantable 
pulse generator) is connected to the respiratory sensor by means of a sensor lead. 
A stimulation lead connects the stimulator to the half-cuff electrode around the 
hypoglossal nerve. 
Notes: Reprinted from J Sleep Res, 23(1), Kezirian eJ, Goding GS Jr, Malhotra A, 
et al, Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month 
outcomes, 77–83, Copyright © 2014, with permission from elsevier.78Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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A more promising method of stimulating upper airway 
muscles to treat OSA, which emerged over a decade ago 
but stalled due to lack of reliable devices,73–76 is hypoglossal 
nerve stimulation (HNS).77–81 In HNS, a silicone cuff with 
stimulating electrodes is surgically placed around a unilateral 
hypoglossal nerve, which includes motor neurons innervat-
ing both protrusor and retractor muscles of the tongue. 
Appropriate placement of the electrode cuff for activation 
of the protrusor muscles is confirmed by observing tongue 
protrusion during stimulation and by electromyographic 
monitoring during surgery. Stimulating leads are tunneled 
subplatysmally via the neck to the neurostimulator, which 
is placed subcutaneously inferior to the clavicle. From the 
neurostimulator, sensory leads are tunneled subcutaneously 
to intercostal muscles to monitor respiration.77–81
The neurostimulator delivers either synchronous77–80 or 
continuous stimulation.81 In synchronous stimulation, sen-
sory leads detect inspiratory efforts that are analyzed by the 
neurostimulator. The neurostimulator’s software algorithm 
predicts the onset of inspiratory effort, delivering stimula-
tion pulses between the end of the expiratory effort and the 
beginning of the next expiratory phase of each respiratory 
cycle. Synchronous stimulation systems depolarize the entire 
hypoglossal nerve during inspiratory effort, causing bulk 
tongue protrusion.76–80 In continuous stimulation, electrodes 
placed around the hypoglossal nerve are continuously and 
sequentially cycled from one electrode to the next in a 
predetermined fashion during the entire respiratory cycle. 
The focus of continuous stimulation is to increase tonic, 
rather than phasic, activation of the genioglossus.76,81 In 
both systems, stimulation periods are maintained on a duty 
cycle of ,50% to prevent neuromuscular fatigue of the 
tongue.76 After patients are implanted, stimulus titration for 
the patient occurs by gradually adjusting stimulus intensity 
(mA), frequency (Hz), and pulse width (µsec) to tolerable 
levels that consistently abolish inspiratory flow restriction 
during sleep.76
Five recent HNS trials had similar inclusion and exclu-
sion criteria. Two trials included participants with moderate 
to severe OSA (pretreatment AHI of 20–100) and BMI #40 
and two trials included those with an AHI of 20–50 and 
BMI #32.77–80 One trial included subjects with AHI $20 and 
BMI between 25 and 40.81 The upper threshold of BMI was 
necessary because previous investigations showed that HNS 
had no therapeutic effect in individuals with elevated BMI.78,80 
Exclusion criteria were similar in all trials, and included prior 
surgery of the head or neck, pronounced anatomic abnor-
malities preventing effective use of HNS, $5% of central 
or mixed apneas, cardiovascular disease, and sleep disorders 
other than OSA.77–81 Two studies further excluded patients 
if palatal complete concentric collapse was observed during 
drug-induced sleep endoscopy (DISE) because absence of 
palatal complete concentric collapse during DISE has been 
shown to predict the therapeutic success of HNS.34,79,80
In all five studies, AHI was decreased by $50% and the 
oxygen desaturation index significantly improved at various 
time points (3, 6, or 12 months) after implantation.80 The 
apnea index and hypopnea index each were significantly 
decreased.77,78,80 There were significant improvements in 
symptoms as quantified by improvements in daily function-
ing, excessive daytime sleepiness, mood, sleep quality, and 
quality of life.77,78,80 In two trials, there were increases in sleep 
efficiency and positive changes in sleep architecture, while 
two other studies showed no differences.77,78,80,81 When OSA 
patients were taken off HNS therapy for at least 5 days, the 
AHI and oxygen desaturation index returned back to levels 
prior to implantation.79 However, there is evidence that one-
night off-stimulation resulted in a similar AHI and oxygen 
desaturation index as the previous on-stimulation night, sug-
gesting that HNS therapy could have residual effects lasting 
for at least one night.82 This insight suggests the intriguing 
possibility of alternate night treatment.82
HNS therapy is initially invasive, requiring surgery, 
and adverse events related to the implantation procedure 
or stimulation therapy have been reported. A majority of 
participants reported minor adverse procedural-related 
events (eg, numbness/pain/swelling/infection at incision site, 
temporary tongue weakness) that resolved with time, pain 
medication, and/or antibiotic treatment, or minor adverse 
therapy-related events (eg, tongue abrasions cause by tongue 
movement over teeth, discomfort associated with stimulation) 
that resolved after acclimation.77,78,80,81 Serious adverse events 
happen infrequently and initially after implantation, and 
involve serious infection at the incision site requiring device 
removal or a subsequent surgical procedure to reposition/
replace the electrode cuff or to repair malfunctioning 
equipment.77,78,80,81 There was also a very small percentage 
of participants who had HNS devices removed due to lack of 
objective and subjective effectiveness. The rate of system-
related or procedural-related serious adverse events was 
between 2% and 29% after implantation.77–80
Phenotyping of upper airway collapse can increase 
the probability of HNS success. The studies above did 
exclude OSA patients who had pronounced upper airway 
  abnormalities, like enlarged tonsils or a modified Mallampati 
score of IV, which would prevent the success of HNS.77–79,81 Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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Moreover, phenotyping for absence of palatal complete 
concentric collapse during DISE improved the success of 
HNS.79,80,83 However, the lack of uniformity in sedation 
methods during DISE, which carries its own risks, and the 
lack of an established consensus on DISE scoring systems 
needs to be addressed before DISE can be widely used to 
phenotype OSA patients for HNS.83
In view of mounting evidence for significant reductions 
in AHI and oxygen desaturation index, and the relatively low 
incidence of serious adverse events, HNS appears to be a 
promising alternative therapy for OSA patients with BMI ,40 
who cannot tolerate or refuse to adhere to CPAP. However, 
larger-scale clinical studies are needed to assess the long-term 
safety of HNS. In addition, it will be important to assess the 
efficacy and safety of HNS in subjects with more severe OSA, 
including comorbidities, as well as in individuals with BMI 
.40. A recent update from the Wisconsin Cohort Study has 
shown an increased prevalence in OSA that is correlated with 
an increase in BMI.84 A growing number of individuals with 
OSA remain at a BMI .40, which may limit the use of HNS 
as a general therapeutic alternative in OSA.
Drug treatment
Oral drugs for treating OSA have focused on five   strategies, 
ie, increasing ventilatory drive (eg, progestagens, theophylline, 
acetazolamide), increasing upper airway tone (eg, serotonergics, 
cholinergics), decreasing rapid eye movement sleep (eg, 
antidepressants, clonidine), increasing arousal threshold (eg, 
eszopiclone), and/or increasing the cross-sectional area or 
reducing the surface tension of the upper airway through topical 
therapy (eg, fluticasone, lubricant).85 A recent Cochrane review 
assessed three decades of clinical trials of various drugs target-
ing these strategies and concluded that “some of the drugs may 
be helpful; however, their tolerability needs to be considered 
in long-term trials”.85 The focus here is to present recent and 
innovative drug treatments for OSA.
A recent and novel approach towards increasing upper 
airway tone to alleviate OSA has been the use of cannabinoids. 
Dronabinol is a nonselective cannabinoid type 1 (CB1) 
and type 2 (CB2) receptor agonist used historically to treat 
anorexia/cachexia associated with acquired immunodeficiency 
syndrome and to control chemotherapy-induced nausea and 
vomiting. At doses of 2.5–10 mg per day, dronabinol signifi-
cantly reduced AHI and improved subjective sleepiness in 17 
adults with moderate to severe OSA, in a single-blind dose-
escalation proof-of-concept clinical trial.86 However, there were 
no changes in oxygen desaturation index, and sleep efficiency 
and arousal index showed improvements only during the first 
half of the night at the highest dose.86 A more recent second-
ary analysis of this study demonstrated a shift in the sleep 
electroencephalogram toward lower frequencies and improved 
ultradian cycling that was predictive of improved alertness.87 
The improvement in AHI was unlikely due to any respiratory 
stimulant effect because animal studies have shown a decreased 
respiratory rate across all sleep/wake states after treatment 
with dronabinol.88 The authors attributed the decrease in AHI 
to increased upper airway tone and observed a significant 
improvement in supine AHI.86 This may reflect inhibition of 
afferent vagal nerve activity, leading to disinhibition of upper 
airway motor neurons. A recent report showing increased pha-
sic activation of genioglossi, and attenuated serotonin-induced 
apnea in rats subjected to local nodose ganglion injections of 
dronabinol supports this interpretation.89 There were no serious 
adverse events associated with daily oral dronabinol. Common 
minor adverse events included evening somnolence (after drug 
administration and before lights out) and increased appetite. 
Although weight gain was not observed during this 3-week 
treatment period, this will need to be confirmed by longer-term 
trials with cannabinoids.86 Larger-scale, randomized controlled 
long-term studies will be needed to establish the efficacy and 
safety of cannabinoids in the treatment of OSA.
Another new therapeutic strategy to treat OSA is to phar-
maceutically modify loop gain.5 Two studies have shown that 
some patients with OSA have high loop gain, and therefore, 
unstable ventilatory systems prone to apneas.90,91 In a recent 
non-blinded study, patients taking acetazolamide 500 mg 
twice daily for 7 days exhibited significantly decreased loop 
gain and AHI when compared with baseline levels.92 This 
improvement in ventilatory stability was attributed to a reduc-
tion in the magnitude of the ventilatory response to arousal. 
The ventilatory system was desensitized to disturbances 
contributing to ventilatory instability.92 Unfortunately, long-
term usage of acetazolamide is poorly tolerated and might 
not be a viable treatment option.5 Randomized, double-blind, 
long-term studies are needed to verify the feasibility of using 
acetazolamide in the treatment of OSA.
OSA has been linked to gastroesophageal reflux dis-
ease (GERD), and several studies suggest that treatment 
of GERD may decrease AHI and daytime sleepiness.93–95 
However, these studies recruited individuals primarily 
for GERD. A recent study consecutively enrolled patients 
with OSA and investigated the effects of a proton pump 
inhibitor,   lansoprazole, on OSA.96 Ninety-one percent 
of participants had pathological reflux episodes, and 22% 
of participants had at least 50% of apneas preceded by a 
reflux event during polysomnography. Three months of Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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twice-daily lansoprazole decreased AHI, but there were no 
changes in oxygen desaturation index or sleep efficiency. 
Proton pump inhibitors are well tolerated, with only weak 
observational associations between proton pump inhibitor 
therapy and fractures,   pneumonia, mortality, and nutritional 
  deficiencies.97 Evaluation of GERD has the potential to 
become standard practice during OSA diagnosis.
The drug therapies listed above have potential in treat-
ing OSA. However, the long-term tolerability and efficacy 
of these drugs remain to be demonstrated. Further basic 
research needs to be conducted to better elucidate the 
  neurobiological mechanisms underlying OSA; bringing 
fresh insights to suggest new (or to modify previous) treat-
ment strategies in OSA. As progress is made in this area, 
the hope for safe and effective pharmacotherapies in OSA 
may become a reality.
Recommendations and conclusion
Few novel treatments have emerged that have proven as effica-
cious as CPAP treatment, especially for more severe disease. 
However, the modest level of treatment adherence makes 
CPAP less effective, underscoring the need for more innova-
tive interventions. For the new approaches that have emerged, 
few have been robustly evaluated in randomized clinical trials 
and those that have had small sample sizes and limited out-
comes. There is no universal definition of treatment success to 
guide determination of the efficacy of innovative treatments. 
However, outcomes that might be included to demonstrate 
treatment effectiveness would be adequate titration (CPAP and 
oral appliance), improved oxygenation, reduction in sleepiness 
(measured by the Epworth Sleepiness Scale), improved daily 
functioning (measured by the Functional Outcomes of Sleep 
Questionnaire), enhanced neurobehavior (metrics of sustained 
attention measured with the Psychomotor Vigilance Task), 
and improved mood (measured with a mood instrument such 
as the Profile of Mood States). In addition to providing the 
definition and outcomes of treatment success, larger clinical 
trials of novel interventions are needed with an evaluation 
of long-term treatment outcomes that reflect the variety of 
impairments associated with OSA.
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